___

• Attardi BJ, Burgenson J, Hild SA, Reel JR (2004). In vitro antiprogestational/antiglucocorticoid activity and progestin and glucocorticoid receptor binding of the putative metabolites and synthetic derivatives of CDB-2914, CDB-4124, and mifepristone. J Steroid Biochem 88: 277–288.
• Attardi BJ, Burgenson J, Hild SA, Reel JR, Blye RP (2002). CDB-4124 and its putative monodemethylated metabolite, CDB-4453, are potent antiprogestins with reduced antiglucocorticoid activity: in vitro comparison to mifepristone and CDB-2914. Mol Cell Endocrinol 188: 111–123.
• Bakker GH, Setyono-Han B, Henkelman MS (1987). Comparison of the actions of the anti-progestin mifepristone (RU486), the progestin megestrol acetate, the LHRH analog buserelin, and ovariectomy in treatment of rat mammary tumors. Cancer Treat Rep 71: 1021–1027.
• Bakker GH, Setyono-Han B, Portengen H, De Jong FH, Foekens JA, Klijn JG (1989). Endocrine and antitumor effects of combined treatment with an antiprogestin and antiestrogen or luteinizing hormone-releasing hormone agonist in female rats bearing mammary tumors. Endocrinology 125: 1593–1598.
• Bakker GH, Setyono-Han B, Portengen H, De Jong FH, Foekens JA, Klijn JG (1990). Treatment of breast cancer with different antiprogestins: preclinical and clinical studies. J Steroid Biochem Mol Biol 37: 789–794.
• Bakker GH, Setyonohan B, Portengen H, Dejong FH, Foekens JA, Klijn JGM (1989). Endocrine and antitumor effects of combined treatment with an antiprogestin and antiestrogen or luteinizing-hormone-releasing hormone agonist in female rats bearing mammary-tumors. Endocrinology 125: 1593–1598.
• Bardon S, Vignon F, Montcourrier P, Rochefort H (1987). Steroid receptor-mediated cytotoxicity of an antiestrogen and an antiprogestin in breast-cancer cells. Cancer Res 47: 1441–1448.
• Baulieu EE (1994). Ru486 - a compound that gets itself talked about. Hum Reprod 9: 1–6.
• Beier HM, Spitz IM (1994). Progesterone antagonists in reproductive medicine and oncology - preface. Hum Reprod 9: R5–R5.
• Bertagna X, Bertagna C, Luton JP, Husson JM, Girard F (1984). The new steroid analog RU 486 inhibits glucocorticoid action in man. J Clin Endocrinol Metab 59: 25–28.
• Chabbert-Buffet N, Meduri G, Bouchard P, Spitz IM (2005). Selective progesterone receptor modulators and progesterone antagonists: mechanisms of action and clinical applications. Hum Reprod Update 11: 293–307.
• Charles NJ, Thomas P, Lange CA (2010). Expression of membrane progesterone receptors (mPR/PAQR) in ovarian cancer cells: implications for progesterone-induced signaling events. Horm Cancer 1: 167–176.
• Chatterton RT, Jr., Lydon JP, Mehta RG, Mateo ET, Pletz A, Jordan VC (2002). Role of the progesterone receptor (PR) in susceptibility of mouse mammary gland to 7,12-dimethylbenz[a]anthracene- induced hormone-independent preneoplastic lesions in vitro. Cancer Lett 188: 47–52.
• Chen W, Ohara N, Wang JY, Xu Q, Liu J, Morikawa A, Sasaki H, Yoshida S, Demanno DA, Chwalisz K, et al. (2006). A novel selective progesterone receptor modulator asoprisnil (J867) inhibits proliferation and induces apoptosis in cultured human uterine leiomyoma cells in the absence of comparable effects on myometrial cells. J Clin Endocr Metab 91: 1296–1304.
• Chlebowski RT, Hendrix SL, Langer RD, Stefanick ML, Gass M, Lane D, Rodabough RJ, Gilligan MA, Cyr MG, Thomson CA, et al. (2003). Influence of estrogen plus progestin on breast, cancer and mammography in healthy postmenopausal women - The Women’s Health Initiative Randomized trial. Jama-J Am Med Assoc 289: 3243–3253.
• Christov K, Grubbs CJ, Shilkaitis A, Juliana MM, Lubet RA (2007). Short-term modulation of cell proliferation and apoptosis and preventive/Therapeutic efficacy of various agents in a mammary cancer model. Clin Cancer Res 13: 5488–5496.
• Christov K, Shilkaitis A, Green A (2003). Tamoxifen selectively modulates the expression of cell cycle regulatory proteins in mammary tumors. Breast Cancer Res Treat 77: 253–264.
• Christov K, Wiehle R (2012). Progesterone receptor modulators induce apoptosis in mammary tumors and uterine leiomyomas. In: Chen GG, Lai PBS, editors. Novel Apoptotic Regulators in Carcinogenesis. Dordrecht, Germany: Springer Science + Business Media, pp. 205–226.
• Daniel AR, Gaviglio AL, Knutson TP, Ostrander JH, D’Assoro AB, Ravindranathan P, Peng Y, Raj GV, Yee D, Lange CA (2014). Progesterone receptor-B enhances estrogen responsiveness of breast cancer cells via scaffolding PELP1- and estrogen receptor-containing transcription complexes. Oncogene doi:10.1038/onc.2013.579.
• Daniel AR, Lange CA (2009). Protein kinases mediate ligand- independent derepression of sumoylated progesterone receptors in breast cancer cells. P Natl Acad Sci USA 106: 14287–14292.
• Donnez J, Tomaszewski J, Vazquez F, Bouchard P, Lemieszczuk B, Baro F, Nouri K, Selvaggi L, Sodowski K, Bestel E, et al. (2012). Ulipristal acetate versus leuprolide acetate for uterine fibroids. New Engl J Med 366: 421–432.
• Dressing GE, Lange CA (2009). Integrated actions of progesterone receptor and cell cycle machinery regulate breast cancer cell proliferation. Steroids 74: 573–576.
• Engman M, Skoog L, Soderqvist G, Gemzell-Danielsson K (2008). The effect of mifepristone on breast cell proliferation in premenopausal women evaluated through fine needle aspiration cytology. Hum Reprod 23: 2072–2079.
• Frank DW, Kitron KT, Murchism TE (1979). Mammary tumors and serum hormones in the bitch treated with medroxy- progesterone acetate or progesterone for four years. Fertil Steril 31: 340–346.
• Grunberg SM (1994). Role of antiprogestational therapy for meningiomas. Hum Reprod 9: 202–207.
• Gupta A, Mehta R, Alimirah F, Peng X, Murillo G, Wiehle R, Mehta RG (2013). Effects and mechanism of action of Proellex, an antiprogestin in aromatase overexpressing and Letrozole resistant T47D breast cancer cells. J Steroid Biochem Molec Biol 133: 30–42.
• Harper MJK, Walpole A (1966). Contrasting endocrine activities of cis and trans isomers in a series of substituted triphenylethylenes. Nature 212: 5087.
• Herman W, Wyss R, Riondel A, Philibert D (1982). The effects of an antiprogesterone steroid in women: interruption of the menstrual cycle and of early pregnancy. C R Acad Sci Paris 94: 933–938.
• Hodgen GD (1991). Antiprogestins: the political chemistry of RU 486. Fertil Steril 50: 36–38.
• Horwitz KB (1993). Antiprogestins and the treatment of breast cancer. In: Donaldson MS, Dorflinger L, Brown SS, Benet LZ, editors. Clinical Applications of Mifepristone (RU 486) and other Antiprogestins Assessing the Science and Recommending a Research Agenda. Washington, DC, USA: National Academy Press, pp. 210–228.
• Huggins C, Moon RC, Morii S (1962). Extinction of experimental mammary cancer. Proc Nat’l Acad Sci USA 48: 379–385.
• Ioffe OB, Zaino RJ, Mutter GL (2009). Endometrial changes from short-term therapy with CDB-4124, a selective progesterone receptor modulator. Modern Pathol 22: 450–459.
• Katiyar P, Ma Y, Riegel A, Fan S, Rosen EM (2009). Mechanism of BRCA1-mediated inhibition of progesterone receptor transcriptional activity. Mol Endocrinol 23: 1135–1146.
• Katzenellenbogen JA, O’Malley BW, Katzenellenbogen BS (1996). Tripartite steroid hormone receptor pharmacology: interaction with multiple effector sites as a basis for the cell- and promoter- specific action of these hormones. Molecular Endocrinology 10: 119–131.
• Kettel LM, Murphy AA, Mortola AJ, Liu JH (1991). Endocrine responses to long-term administration of the anti-progesterone RU486 in patients with pelvic endometriosis. Fertil Steril 56: 402–407.
• Klijn JGM, Dejong FH, Bakker GH, Lamberts SWJ, Rodenburg CJ, Alexieva-Figusch J (1989). Antiprogestins, a new form of endocrine therapy for human-breast cancer. Cancer Res 49: 2851–2856.
• Klijn JGM, Setyono-Han B, Foekens JA (2000). Progesterone antagonists and progesterone receptor modulators in the treatment of breast cancer. Steroids 65: 825–830.
• Kloosterboer HJ, Deckers GH, Schoonene WGE (1994). Pharmacology of two new very selective antiprogestagens: Org 31710 and ORG 31806. Hum Reprod 9 Suppl 1: 47–52.
• Liang Y, Besch-Williford C, Brekken RA, Hyder SM (2007). Progestin- dependent progression of human breast tumor xenografts: a novel model for evaluating antitumor therapeutics. Cancer Res 67: 9929–9936.
• Lin VCL, Ng EH, Aw SE, Tan MG-K (1999). Progestins inhibit the growth ofMDA_MB_231 cells transfected with progesterone receptor cDNA. Clin Cancer Res 5: 395–404.
• Lin VCL, Woon CT, Aw SE, Guo CH (2003). Distinct molecular pathways mediate progesterone-induced growth inhibition and focal adhesion. Endocrinology 144: 5650–5657.
• Liu JH, Garzo G, Morris S, Stuenkel C, Ulmann A, Yen SS (1987). Disruption of follicular maturation and delay of ovulation after administration of the antiprogesterone RU486. J Clin Endocrinol Metab 65: 1135–1140.
• Luo X, Yin P, Coon JS, Cheng YH, Bulun SE (2010). The selective progesterone receptor modulator CDB4124 inhibits proliferation and induces apoptosis in uterine leiomyoma cells. Reprod Sci 17: 271a–271a.
• Mandelonde T, Romieu, G, Ulmann A, Pujol H, Grenier J, Khalaf S, Cavalie G, Rochefort H (1987). First clinical trial on the use of the antiprogestin RU 486 in advanced breast cancer. In: Klijn JGM, Paridaens R, Foekens JA, editors. Hormonal Manipulation of Cancer: Peptides, Growth Factors, and New (Anti-) Steroidal Agents. New York, NY, USA, Raven Press, pp. 55–65.
• Michna H, Schneider MR, Nishino Y, el Etreby MF (1989). Antitumor activity of the antiprogestins ZK 98.299 and RU 38.486 in hormone dependent rat and mouse mammary tumors: mechanistic studies. Breast Cancer Res Treat 14: 275–288.
• Michna H, Schneider MR, Nishino Y, Eletreby MF (1989). The antitumor mechanism of progesterone antagonists is a receptor mediated antiproliferative effect by induction of terminal cell- death. J Steroid Biochem 34: 447–453.
• Mutter GL, Bergeron C, Deligdisch L, Ferenczy A, Glant M, Merino M, Williams AR, Blithe DL (2008). The spectrum of endometrial pathology induced by progesterone receptor modulators. Modern Pathol 21: 591–598.
• Nagasawa H, Aoki M, Sakagami N, Ishida M (1988). Medroxyprogesterone acetate enhances spontaneous mammary tumorigenesis and uterine adenomyosis in mice. Breast Cancer Res Tr 12: 59–66.
• Nishino Y, Schneider MR, Michna H (1994). Enhancement of the antitumor efficacy of the antiprogestin, onapristone, by combination with the antiestrogen, Ici-164384. J Cancer Res Clin 120: 298–302.
• Ortmann O, Catt KJ, Schulz KD, Emons G (1994). Modulatory action of progesterone and progesterone antagonists on hypothalamic-pituitary function. Hum Reprod 9: 53–62.
• Perrault D, Eisenhauer EA, Pritchard KI, Panasci L, Norris B, Vandenberg T, Fisher B (1996). Phase II study of the progesterone antagonist mifepristone in patients with untreated metastatic breast carcinoma: A National Cancer Institute of Canada Clinical Trials Group Study. J Clin Oncol 14: 2709–2712.
• Philibert D (1984). RU 38486: an original, multifaceted antihormone in vivo. In: Agarwal MK, editor, Adrenal Steroid Antagonism. Berlin, Germany: Walter de Gruyter and Co, pp. 77–101.
• Philibert D, Deraedt R, Teustsch G, Tournemine C, Sakiz E (1982). A new lead for steroidal antihormone. 64th Annual Meeting of the Endocrine Society, San Francisco Abstr 668.
• Philibert D, Deraedt R, Teutsch G (1981). 38486: a potent antiglucocorticoid in vivo. 8th International Congress of Pharmacology Abstr 1463.
• Poole AJ, Li Y, Kim Y, Lin SC, Lee WH, Lee EY (2006). Prevention of Brca1-mediated mammary tumorigenesis in mice by a progesterone antagonist. Science 314: 1467–1470.
• Poole AJ, Li Y, Kim Y, Lin SCJ, Lee WH, Lee EYHP (2006). Prevention of Brca1-mediated mammary tumorigenesis in mice by a progesterone antagonist. Science 314: 1467–1470.
• Robertson JFR, Willsher PC, Winterbottom L, Blamey RW, Thorpe S (1999). Onapristone, a progesterone receptor antagonist, as first-line therapy in primary breast cancer. Eur J Cancer 35: 214–218.
• Roeder H, Jayes F, Feng L, Leppert PC (2011). CDB-4124 does not cause apoptosis in cultured fibroid cells. Reprod Sci 18: 850– 852.
• Rohan TE, Negassa A, Chlebowski RT, Lasser NL, McTiernan A, Schenken RS, Ginsberg M, Wassertheil-Smoller S, Page DL (2008). Estrogen plus progestin and risk of benign proliferative breast disease. Cancer Epidem Biomar 17: 2337–2343.
• Romieu G, Maudelonde T, Ulmann A, Pujol H, Grenier J, Cavalie G, Khalaf S, Rochefort H (1987). The antiprogestin Ru486 in advanced breast cancer: preliminary clinical trial. Bull Cancer 74: 455–461.
• Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SAA, Howard BV, Johnson KC, et al. (2002). Risks and benefits of estrogen plus progestin in healthy postmenopausal women - principal results from the Women’s Health Initiative randomized controlled trial. Jama-J Am Med Assoc 288: 321–333.
• Skorupskaite K, George JT, Anderson RA (2014). The kisspeptin- GnRH pathway in human reproductive health and disease. Hum Reprod Update 20: 485–500.
• Spitz IM (2009). Clinical utility of progesterone receptor modulators and their effect in the endometrium. Curr Opin Obstet Gynecol 21: 318–324.
• Spitz IM, Wiehle RD, van As A (2009). Progesterone receptor modulators in endometriosis: a new therapeutic option. In: Garcia-Velasco J, Rizk B, editors. Endometriosis: Current Management and Future Trends. New Delhi, India: Jaypee, pp. 225–234.
• Vicent GP, Ballare C, Zaurin R, Saragueta P, Beato M (2006). Chromatin remodeling and control of cell proliferation by progestins via cross talk of progesterone receptor with the estrogen receptors and kinase signaling pathways. Ann NY Acad Sci 1089: 59–72.
• Welsch CW (1985). Host factors affecting the growth of carcinogen- induced rat mammary carcinomas - a review and tribute to Huggins, Charles, Brenton. Cancer Res 45: 3415–3443.
• Wiehle R, Lantvit D, Yamada T, Christov K (2011). CDB-4124, a progesterone receptor modulator, inhibits mammary carcinogenesis by suppressing cell proliferation and inducing apoptosis. Cancer Prev Res 4: 414–424.
• Wiehle RD, Christov K, Mehta R (2007). Antiprogestin suppresses growth of established tumors induced by 7,12-dimethylbenz(a) anthracene: comparison between RU486 and a new 21-substituted-19-nor-progestins. Oncol Reports 18: 167–174.
• Wiehle RDW, Goldberg J, Brodniewicz T (2008). Effects of a new progesterone receptor modulator, CDB-4124, on fibroid size and uterine bleeding. US Obstet Gynaecol 3: 17–20.
• Xu Q, Takekida S, Ohara N, Chen W, Sitruk-Ware R, Johansson EDB, Maruo T (2005). Progesterone receptor modulator CDB-2914 down-regulates proliferative cell nuclear antigen and Bcl-2 protein expression and up-regulates caspase-3 and poly(adenosine 5 ‘-diphosphate-ribose) polymerase expression in cultured human uterine leiomyoma cells. J Clin Endocr Metab 90: 953–961.